Titan Pharmaceuticals Inc. (NASDAQ:TTNP) does about 9.78M shares in volume on a normal day but saw 4952699 shares change hands in Tuesday trading. The company now has a market cap of 20.30M USD and an enterprise value of about $22.80M. Its current market price is $0.21, marking a decrease of -7.84% compared to the previous close of $0.23. The 52 week high reached by this stock is $0.59 whilst the lowest price level in 52 weeks is $0.14. The script in recent trading has seen the stock touch a high of $0.23 and a low of $0.21.

Titan Pharmaceuticals Inc. (TTNP) has a 20-day trading average at $0.2659 and the current price is -63.88% off the 52-week high compared with 49.79% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2936 and its 200-day simple moving average is $0.2601. If we look at the stock’s price movements over the week, volatility stands at 5.55%, which increases to 6.21% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 26.38 to suggest the stock is oversold.

1 analysts observing the Titan Pharmaceuticals Inc. (TTNP) stock have set the 12-month price targets for the company’s shares at between $0.80 and $1.00. The median price target is 76.67% away from the current levels at $0.90.

FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 0 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 26, 2019 when Maxim Group initiated the stock to “Buy” and issued a price target of $4. ROTH Capital downgraded the stock to “Neutral” from Buy on November 10, 2017 at a price target of .

The current price level is -21.44%, -28.12%, and -18.18% away from its SMA20, SMA50, and SMA200 respectively, with the TTNP price moving above the 50-day SMA on September 01. Titan Pharmaceuticals Inc. (TTNP) stock is down -11.19% over the week and -28.72% over the past month. Its price is 9.58% year-to-date and -56.38% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.05 below consensus estimates by -$0.02. The company’s next earnings report is expected on 11/05/2020, with forecasts estimating quarterly EPS at -$0.03 and -$0.16 for whole year. TTNP’s earnings per share are forecast to grow by 77.80% this year and 12.50% over next year. Expected sales for next quarter are $1.65 million, which analysts say will come at $5.23 million for the current fiscal year and next year at $5.09 million. In addition, estimates put the company’s current quarterly revenue at an average of $900k.

Its 12-month price target is $0.90. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $0.80, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $1.00.

Outstanding shares total 95.66M with insiders holding 0.30% of the shares and institutional holders owning 5.68% of the company’s common stock. The company has a return on investment of -307.70%. The beta has a value of 0.81. Price to book ratio is 10.63 and price to sales ratio is 4.23.

According to a U.S. Securities and Exchange Commission filing, Vanguard Extended Market Index Fu has reduced its position in Titan Pharmaceuticals Inc. (TTNP) to 1,150,353 shares, mirroring a recent drop by 0.00%. Vanguard Extended Market Index Fu dumped 0.0 shares of Titan Pharmaceuticals Inc. common stock bringing its total worth to about $0.33 million at the end of recent close, SEC documents show. Vanguard Extended Market Index Fu isn’t the only investment manager who changed stakes and is followed by Fidelity Extended Market Index Fu, which sold off 0.0 shares to end up with 406,523 shares worth $0.12 million. Fidelity Series Total Market Inde cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.08% position in Titan Pharmaceuticals Inc. thanks to 73037.0 shares amounting to $21254.0.